Discover the unmet need of patients with uveitic glaucoma, an end-stage disease comprised of two serious eye conditions: non infectious uveitis and glaucoma. %
Employees: 1-10
Mentions in press and media 10
| Date | Title | Description |
| 12.12.2025 | USD 5 million to accelerate ALLEGRIA’s anti-allergy portfolio | Alongside ALK Abelló, ALLEGRIA’s funding round also saw the participation of HighLight Capital (HLC), Lichtsteiner Foundation and co-founding investor Forty51 Ventures. The investment sets the stage for accelerated growth and value creatio... |
| 10.06.2025 | Mosanna Therapeutics: A Breath of Fresh Air in Sleep Apnea Treatment | In the realm of healthcare, innovation often emerges from the shadows of necessity. Mosanna Therapeutics, a biotech company based in Redwood City, California, is stepping into the spotlight with a groundbreaking approach to treating obstruc... |
| 10.06.2025 | Mosanna Therapeutics raises USD 80 million to advance sleep apnea nasal spray | Mosanna Therapeutics, the clinical-stage biotech company headquartered in Basel, is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body’s natural ai... |
| 09.06.2025 | EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray | EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray Mon, Jun 09, 2025 16:15 CET Report this content Series A Funding will be used to advance Mosanna’s nasal spray therapy ... |
| 24.06.2024 | Melodia Therapeutics launched with in-licensing deal | MDI-0151 is a clinical candidate compound from the Alivexis’ discovery program MOD-A, focused on Cathepsin C inhibition. Cathepsin C is an enzyme responsible for the activation of a group of proteases that play an important role in the des... |
| 08.05.2024 | USD 3.5 Million to tackle allergies and inflammatory diseases | An increasing number of patients experience the effects of allergies and inflammatory diseases, including chronic urticaria, mast-cell-driven syndrome, and food allergy, impacting their quality of life. The associated socio-economic burden... |
| 21.08.2023 | Mysthera Therapeutics launches with USD 3.5 million seed round | |
| 21.07.2022 | FORTY51 Ventures Holds First Close of Fund I and First Investment | Luxembourg-based FORTY51 Ventures raised USD43M in the first close FORTY51 Ventures I. FORTY51 Ventures is anchored by a strong institutional investor syndicate with Stable Asset Management, as well as the Fischli Family. Seasoned Biotech e... |
| 18.07.2022 | Biotech VC FORTY51 announces first close of Fund I | |
| 15.07.2022 | Mosanna Therapeutics completes seed round |